Drug updated on 9/5/2024
| Dosage Form | injectable (intravenous; 15.5 MBq/mL to 308.2 MBq/mL [0.42 mCi/mL to 8.33 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Latest News
Summary
- Fluorodopa F 18 (fluorodopa F 18) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- Juvenile Parkinsonism (JP) and Dopamine Responsive Dystonia (DRD): Fluorodopa (FD) PET scans showed significantly decreased uptake in the putamen and caudate nucleus in JP patients, while DRD patients exhibited uptake patterns similar to normal subjects with only slight reductions.
- Brain Tumors (Gliomas): 18F-FDOPA PET was more effective than 18F-FDG PET/CT in managing gliomas, demonstrating utility across stages, including diagnosis, grading, treatment assessment, and prognosis. The studies focused on glioma patients without detailed subgroup analysis.
- Recurrent Medullary Thyroid Carcinoma (MTC): F-DOPA PET outperformed FDG PET and other radiopharmaceuticals in detection rates for recurrent MTC, showing the highest effectiveness regardless of serum calcitonin or CEA levels and calcitonin doubling time.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Fluorodopa F 18 (fluorodopa F 18) Prescribing Information. | 2019 | The Feinstein Institutes for Medical Research, Manhasset, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Relevance of fluorodopa PET scan in dopamine responsive dystonia and juvenile parkinsonism: a systematic review. | 2023 | Neurology International |
| Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. | 2020 | Cancer Imaging |
| Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. | 2020 | Clinical Nuclear Medicine |
| Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. | 2019 | International Journal of Molecular Sciences |